These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29886095)

  • 1. Targeted delivery of pixantrone to neutrophils by poly(sialic acid)-p-octadecylamine conjugate modified liposomes with improved antitumor activity.
    Luo X; Liu M; Hu L; Qiu Q; Liu X; Li C; Lu M; Liu Y; Zhang T; Zhou S; McClements DJ; Jia X; Deng Y; Song Y
    Int J Pharm; 2018 Aug; 547(1-2):315-329. PubMed ID: 29886095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-mediated delivery of pixantrone-loaded liposomes decorated with poly(sialic acid)-octadecylamine conjugate for lung cancer treatment.
    Luo X; Hu L; Zheng H; Liu M; Liu X; Li C; Qiu Q; Zhao Z; Cheng X; Lai C; Su Y; Deng Y; Song Y
    Drug Deliv; 2018 Nov; 25(1):1200-1212. PubMed ID: 29791241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate.
    She Z; Zhang T; Wang X; Li X; Song Y; Cheng X; Huang Z; Deng Y
    Biomaterials; 2014 Jun; 35(19):5216-25. PubMed ID: 24703714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are third-generation active-targeting nanoformulations definitely the best? In vitro and in vivo comparisons of pixantrone-loaded liposomes modified with different sialic acid derivatives.
    Song Y; She Z; Huang Z; Wang S; Liu X; Zhang Q; Sun J; Di D; Deng Y
    Drug Deliv Transl Res; 2022 Mar; 12(3):647-661. PubMed ID: 33928513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
    Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
    Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacodynamics of liposomes modified with different chain length of sialic acid derivatives].
    Song YZ; Huang ZJ; Luo X; Wang MJ; Zheng JH; Shi J; Deng YH
    Yao Xue Xue Bao; 2016 Feb; 51(2):316-24. PubMed ID: 29856587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-Mediated Delivery of Dexamethasone Palmitate-Loaded Liposomes Decorated with a Sialic Acid Conjugate for Rheumatoid Arthritis Treatment.
    Hu L; Luo X; Zhou S; Zhu J; Xiao M; Li C; Zheng H; Qiu Q; Lai C; Liu X; Deng Y; Song Y
    Pharm Res; 2019 May; 36(7):97. PubMed ID: 31076925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sialic Acid Conjugate-Modified Liposomal Dexamethasone Palmitate Targeting Neutrophils for Rheumatoid Arthritis Therapy: Influence of Particle Size.
    Wang S; Yang S; Lai X; Song Y; Hu L; Li C; Shi T; Liu X; Deng Y; Chen G
    AAPS PharmSciTech; 2021 Jan; 22(1):16. PubMed ID: 33389218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sialic acid-conjugate modified liposomes targeting neutrophils for improved tumour therapy.
    Li C; Qiu Q; Liu M; Liu X; Hu L; Luo X; Lai C; Zhao D; Zhang H; Gao X; Deng Y; Song Y
    Biomater Sci; 2020 Apr; 8(8):2189-2201. PubMed ID: 32096498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid-octadecylamine conjugate.
    Sun J; Song Y; Lu M; Lin X; Liu Y; Zhou S; Su Y; Deng Y
    Eur J Pharm Sci; 2016 Oct; 93():177-83. PubMed ID: 27539143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy.
    Ding J; Zhao D; Hu Y; Liu M; Liao X; Zhao B; Liu X; Deng Y; Song Y
    Int J Pharm; 2019 Nov; 571():118706. PubMed ID: 31593811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Dose on Neutrophil-Mediated Delivery of Nanoparticles for Tumor-Targeting Therapy Strategies.
    Liu M; Li C; NaYan ; Zhao D; Zhang H; Li J; Tang X; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2021 Mar; 22(3):89. PubMed ID: 33665749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Liu X; Song Y; Deng Y
    Drug Deliv Transl Res; 2018 Jun; 8(3):602-616. PubMed ID: 29536348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Song Y; Liu X; Deng Y
    Int J Pharm; 2016 Dec; 515(1-2):449-459. PubMed ID: 27789365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy.
    Ding J; Sui D; Liu M; Su Y; Wang Y; Liu M; Luo X; Liu X; Deng Y; Song Y
    Acta Biomater; 2021 Oct; 134():702-715. PubMed ID: 34339869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
    Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
    Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
    Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialic acid-decorated liposomes enhance the anti-cancer efficacy of docetaxel in tumor-associated macrophages.
    Tran NP; Tran P; Yoo SY; Tangchang W; Lee S; Lee JY; Son HY; Park JS
    Biomater Adv; 2023 Nov; 154():213606. PubMed ID: 37678087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections.
    Negishi Y; Hamano N; Sato H; Katagiri F; Takatori K; Endo-Takahashi Y; Kikkawa Y; Nomizu M
    Biol Pharm Bull; 2018; 41(7):1107-1111. PubMed ID: 29962407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system.
    Chen B; Dai W; Mei D; Liu T; Li S; He B; He B; Yuan L; Zhang H; Wang X; Zhang Q
    J Control Release; 2016 Nov; 241():68-80. PubMed ID: 27641831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.